Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 MonthsMarketBeat · Oct 2, 2026
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire · Sep 30, 2026
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptSeeking Alpha · Sep 28, 2026
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisBusiness Wire · Sep 28, 2026
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisBusiness Wire · Sep 25, 2026
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?Zacks Investment Research · Sep 3, 2026Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$1.69 | -$1.99 | Miss |
| May 13, 2026 | -$2.93 | -$1.88 | Beat |
| Mar 12, 2026 | -$2.99 | -$2.94 | Beat |
| Nov 5, 2025 | -$4.16 | -$4.64 | Miss |
| Aug 7, 2025 | -$4.86 | -$5.44 | Miss |
| May 6, 2025 | -$5.31 | -$4.96 | Beat |